Tirofiban is a synthetic platelet glycoprotein IIb/IIIa receptor antagonist used in the treatment of patients with non-ST-segment elevation acute coronary syndromes, or ACSs. It helps reduce thrombosis and is often used in combination with other drugs such as aspirin and clopidogrel. In this blog post, we will look at what tirofiban is and how it works, as well as its benefits for medical professionals. We will also discuss potential side effects and contraindications when considering adding tirofiban to a patient’s treatment plan. With this information, healthcare professionals can make an informed decision on whether or not tirofiban is applicable for their patient.
Tirofiban is a non-peptide, small molecule inhibitor of platelet glycoprotein IIb/IIIa. It is used in combination with aspirin and heparin to treat unstable angina and non-ST segment elevation myocardial infarction. Tirofiban has also been shown to be effective in the treatment of ST segment elevation myocardial infarction when used in combination with aspirin and clopidogrel. The benefits of tirofiban include its ability to rapidly and effectively inhibit platelet aggregation, its high degree of specificity for platelet glycoprotein IIb/IIIa, and its relatively short half-life.
Tirofiban is a direct inhibitor of factor XIa. It works by binding to and inhibiting factor XIa, thereby preventing the activation of factor XII and thrombin generation. This results in a decrease in clotting activity and an increase in bleeding time.
Tirofiban is a highly effective antithrombotic agent that has a wide range of benefits for medical professionals. Tirofiban is a reversible inhibitor of the platelet glycoprotein IIb/IIIa receptor and has demonstrated efficacy in the prevention and treatment of thrombotic events. The most common use of tirofiban is in the perioperative setting to prevent thrombosis and keep blood flowing smoothly through the surgical site. Tirofiban has also been shown to be effective in the treatment of acute myocardial infarction, stroke, and unstable angina. In addition, tirofiban has been shown to be safe and well-tolerated in clinical trials.
Tirofiban is a potent platelet inhibitor and as such, can cause serious bleeding. The most common side effects are oozing from intravenous sites and epistaxis (nose bleeds). Less common side effects include gastrointestinal bleeds, brain bleeds, and hemorrhagic strokes. While the incidence of these more serious side effects is low, they can be life-threatening. Therefore, it is important that patients on tirofiban be closely monitored for any signs or symptoms of bleeding.
Tirofiban is a glycoprotein IIb/IIIa inhibitor used to treat patients with acute coronary syndrome (ACS). It is indicated for use in combination with aspirin and heparin in patients who are undergoing percutaneous coronary intervention (PCI). Tirofiban has been shown to improve outcomes in ACS patients, including reducing the risk of death, myocardial infarction, and stroke.
Tirofiban should be considered for use in all patients with ACS who are undergoing PCI. In addition, tirofiban may be considered for use in high-risk ACS patients who are not undergoing PCI but who are at risk for ischemic events.
Tirofiban is a prescription medication used to treat coronary artery disease. It is an oral medication taken twice daily with or without food. Tirofiban should be taken at the same time each day to maintain an even level of medication in your blood.
There are a few potential drug interactions with tirofiban that medical professionals should be aware of. When taken with other medications that increase the risk of bleeding, there is an increased risk for serious bleeding events with tirofiban. This includes medications such as aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), and warfarin. There is also an increased risk for bleeding when tirofiban is taken with certain platelet inhibitors such as clopidogrel. There is a potential for reduced efficacy of tirofiban when taken with CYP3A4 inhibitors such as ketoconazole or grapefruit juice. Finally, tirofiban may increase the levels of certain medications that are metabolized by CYP3A4 such as simvastatin.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Aspirin Fails to Boost Survival in Colorectal Cancer Trial
2.
Do Anatomy Atlases Reflect Social Inequalities?
3.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
4.
Some triple negative breast cancers might be avoided by longer breastfeeding
5.
Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Metabolic Competition Within the Tumor Ecosystem: Mechanisms, Clinical Relevance, and Therapeutic Advances
3.
Ferroptosis-Modulating Nanocarriers for Solid Tumor Therapy
4.
Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients
5.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Excellence in Hematology
2.
Navigating the Complexities of Ph Negative ALL - Part I
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Understanding the causes of anemia in adults beyond nutritional deficiencies
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation